Precision medicine initiative aims to use advances in clinical and basic research to develop therapeutics that selectively target and kill cancer cells. This allows researchers to develop chemically tractable probes that can image cancer in Vivo. Precision medicine is used to treat children or adolescent patients suffering from brain tumor that have no other effective therapies. Various companies are continuously investing in research and development to further refine precision medicines for interventional surgical imaging, as well as for diagnostic and therapeutic applications. In 2015, Pfizer, Inc. established Center of Excellence in Precision Medicine (CEPM) in Chile, in partnership with Thermo Fisher Scientific, to validate new, more precise, and less invasive technologies for diagnosing cancer.
Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/145
Furthermore, precision medicine is proving to be effective in treating oncology-related diseases, cardiovascular diseases, psychiatric disorders, neurodegenerative diseases, arthritis, obesity, diabetes, pain, and Alzheimer’s disease. Reduced cost of treatment attracts patient toward the precision medicine, as precision medicine cuts down most of the expensive treatments, which are not required since genetic testing helps the oncologists offer precision medicine.
The two recent FDA drug approvals, Kalydeco (ivacaftor) and Keytruda (pembrolizumab), pertaining to 33 cystic fibrosis mutations and cancer treatment based on a genetic feature respectively, point to an encouraging future for precision medicine. National Cancer Institute (NCI) conducts NCI-COG Pediatric MATCH trial that enrolls children and adolescents by advanced cancer therapy based on their genetic abnormality, where NCI also plans to support new immunotherapy clinical trials, antibody, testing of new combinations of the cell, small molecule, and radiation therapy studies, which include sequencing of tumor specimens. In July 2017, NCI has also launched various precision medicine trials, which include Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST), Lung Cancer Master Protocol (Lung-MAP), Molecular Analysis for Therapy Choice (NCI-MATCH), and Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT).
Government initiative for precision medicine is expected to fuel the growth of the precision medicine market in the near future.
North America accounts for the largest share in the global precision medicine market, followed by Europe. This is mainly attributed to awareness and initiative related to precision medicine in the North America. In 2015 President Obama announced the launch of Precision Medicine Initiative, that aimed to revolutionize the way of treatment to improve the health, as precision medicine provide an innovative approach that studies the unique gene sequences of individual and offer the tailored treatment. Precision Medicine Initiative have led to powerful novel discoveries and several advanced treatments, which are tailored for specific characteristic such as, genetic makeup or genetic profile of an individual tumor that helps to transform the way of treatment and favors the growth of precision medicine market in near future. The precision medicine initiative invested US$215 million in the National Institutes of Health in fiscal 2016 budget, which is expected to accelerate biomedical research by providing advanced tools and innovative therapies to the physicians, which are tailored according to individual need, in turn fueling the growth of precision medicine market in near future.
Key companies covered as a part of this study include Novartis AG, Intomics, Ferrer Incode, Nanostring Technologies, Inc., Pfizer, Inc., Teva Pharmaceuticals, Merck & Co., Inc., Qiagen N.V., and Quest Diagnostics